Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated ...
The U.S. Food and Drug Administration on Thursday launched an online searchable database listing contaminant levels in human ...
U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...
The FDA unveiled the Chemical Contaminants Transparency Tool, a searchable online database that provides a list of chemical contaminant types and levels used to evaluate possible harm in foods meant ...
Plus Therapeutics (PSTV) announces the U.S. Food and Drug Administration, FDA, has conditionally accepted the Company’s new proprietary name, ...
Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...
Creative Medical Technology Holdings announced that the U.S. Food and Drug Administration has cleared an expanded dose escalation for its ongoing Phase 1/2 trial of StemSpine usin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback